Wei Li

7PUBLICATIONS
5CO-AUTHORS
Biologically active moleculesCheminformatics and quantitative structure-activity relationshipsBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 29, 2026
Pharmacological Characterization of SLL-022CCP, a Selective κ‑Opioid Receptor Agonist with Potent Antinociceptive Effects and Low Central Side Effects.

|Jul 28, 2025
Structure-Activity Relationship of N-Cyclopropylmethyl-7α-[para-(arylcarboxamido)phenyl]-6,14-endoethano-tetrahydronorthebaines as Potent and Selective Kappa Opioid Receptor Agonists.

Linghui Kong, Songyu Yao, Denggao Zhang

|Nov 29, 2024
Discovery of Novel N-Sulfonamide-tetrahydroquinolines as Potent Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists for the Treatment of Psoriasis.

Lunan Lv, Baiyu Chen, Yang Gao

|Apr 22, 2024
Discovery of an Ortho-Substituted N-Cyclopropylmethyl-7α-phenyl-6,14-endoethano-tetrahydronorthebaine Derivative as a Selective and Potent Kappa Opioid Receptor Agonist with Subsided Sedative Effect.

Zixiang Li, Rufeng Ye, Qian He

|Sep 04, 2023
Drug design education in China.

Wei Fu, Wei Li, Boyu Chen

|Jul 28, 2022
SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity.

Linghui Kong, Xuelian Shu, Siyuan Tang

Pageof 2

Frequent Collaborators

5 joint publications

Wei Fu

5 joint publications

Liming Shao

4 joint publications

Linghui Kong

3 joint publications

Qiong Xie